Effect of Integrated Treatment with Traditional Chinese Medicine on Hashimoto’s Thyroiditis Patients

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Journal of Clinical Pharmacy and Therapeutics Pub Date : 2023-10-10 DOI:10.1155/2023/5574095
Xudan Lou, Yuxin Huang, Jieyuzhen Qiu, Jiao Sun, Qin Gu, Haidong Wang, Xiaoming Tao, Cuiping Jiang
{"title":"Effect of Integrated Treatment with Traditional Chinese Medicine on Hashimoto’s Thyroiditis Patients","authors":"Xudan Lou, Yuxin Huang, Jieyuzhen Qiu, Jiao Sun, Qin Gu, Haidong Wang, Xiaoming Tao, Cuiping Jiang","doi":"10.1155/2023/5574095","DOIUrl":null,"url":null,"abstract":"What is Known and Objective. To explore the effects of traditional Chinese medicine (TCM) combined with levothyroxine (L-T4) on thyroid autoantibodies, inflammation, and sleep quality in Hashimoto’s thyroiditis patients. Methods. Patients were randomly divided into group A and group B. Group A was treated with L-T4 alone, while group B was treated with integrated TCM and L-T4. TCM symptoms were quantified before and after treatment as well as PSQI. Blood samples were taken to detect clinical indicators and thyroid autoantibodies. Cytokines in serum and thyroid tissues were analyzed by ELISA and RT-PCR. Results and Discussion. Totally, 196 patients were enrolled in the study, and there were no differences between group A and group B at the baseline. TCM treatment effectively reduced the levels of TGAb and TPOAb and was a protective factor for the improvement of Hashimoto’s thyroiditis antibody titers, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\"> <mi>p</mi> <mtext> </mtext> <mo><</mo> <mtext> </mtext> <mn>0.05</mn> </math> . The serum expressions of IL-17A, IL-6, and IFN-γ in group B after treatment were lower than those in group A and before, while the IL-10 level was raised from the baseline, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M2\"> <mi>p</mi> <mtext> </mtext> <mo><</mo> <mtext> </mtext> <mn>0.05</mn> </math> . Similar results were found in the comparison of IL-17A, IFN-γ, and IL-10 in thyroid tissues of group A, B, and control, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M3\"> <mi>p</mi> <mtext> </mtext> <mo><</mo> <mtext> </mtext> <mn>0.05</mn> </math> . Besides, with integrated treatment, all TCM symptoms except for poor memory were improved as well as sleep quality and mood, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M4\"> <mi>p</mi> <mtext> </mtext> <mo><</mo> <mtext> </mtext> <mn>0.05</mn> </math> . However, these changes were not observed before and after treatment with L-T4 in group A. What is New and Conclusion. The integrated treatment with TCM had a significant effect on thyroid autoantibodies, inflammation, and sleep quality in Hashimoto’s thyroiditis patients and provided a new and effective method for future treatment.","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"247 1","pages":"0"},"PeriodicalIF":2.1000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/5574095","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

What is Known and Objective. To explore the effects of traditional Chinese medicine (TCM) combined with levothyroxine (L-T4) on thyroid autoantibodies, inflammation, and sleep quality in Hashimoto’s thyroiditis patients. Methods. Patients were randomly divided into group A and group B. Group A was treated with L-T4 alone, while group B was treated with integrated TCM and L-T4. TCM symptoms were quantified before and after treatment as well as PSQI. Blood samples were taken to detect clinical indicators and thyroid autoantibodies. Cytokines in serum and thyroid tissues were analyzed by ELISA and RT-PCR. Results and Discussion. Totally, 196 patients were enrolled in the study, and there were no differences between group A and group B at the baseline. TCM treatment effectively reduced the levels of TGAb and TPOAb and was a protective factor for the improvement of Hashimoto’s thyroiditis antibody titers, p < 0.05 . The serum expressions of IL-17A, IL-6, and IFN-γ in group B after treatment were lower than those in group A and before, while the IL-10 level was raised from the baseline, p < 0.05 . Similar results were found in the comparison of IL-17A, IFN-γ, and IL-10 in thyroid tissues of group A, B, and control, p < 0.05 . Besides, with integrated treatment, all TCM symptoms except for poor memory were improved as well as sleep quality and mood, p < 0.05 . However, these changes were not observed before and after treatment with L-T4 in group A. What is New and Conclusion. The integrated treatment with TCM had a significant effect on thyroid autoantibodies, inflammation, and sleep quality in Hashimoto’s thyroiditis patients and provided a new and effective method for future treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中西医结合治疗桥本甲状腺炎疗效观察
已知的和客观的。探讨中药联合左旋甲状腺素(L-T4)对桥本甲状腺炎患者甲状腺自身抗体、炎症及睡眠质量的影响。方法。将患者随机分为A组和B组。A组采用L-T4单药治疗,B组采用中医联合L-T4治疗。量化治疗前后中医症状及PSQI。采血检测临床指标及甲状腺自身抗体。ELISA和RT-PCR检测血清和甲状腺组织细胞因子。结果和讨论。研究共纳入196例患者,A组和B组在基线时无差异。中医药治疗可有效降低TGAb和TPOAb水平,是桥本甲状腺炎抗体效价提高的保护因素,p <0.05。治疗后B组血清IL-17A、IL-6、IFN-γ表达均低于A组及治疗前,IL-10水平较治疗前升高,p <0.05。比较A组、B组和对照组甲状腺组织中IL-17A、IFN-γ和IL-10, p <0.05。综合治疗后,除记忆力差外,其他中医症状均有改善,睡眠质量和情绪均有改善,p <0.05。而a组在L-T4治疗前后未见上述变化。中医综合治疗对桥本甲状腺炎患者甲状腺自身抗体、炎症及睡眠质量均有显著影响,为今后治疗提供了新的有效方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.10
自引率
5.00%
发文量
226
审稿时长
6 months
期刊介绍: The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including: Rational therapeutics Evidence-based practice Safety, cost-effectiveness and clinical efficacy of drugs Drug interactions Clinical impact of drug formulations Pharmacogenetics Personalised, stratified and translational medicine Clinical pharmacokinetics.
期刊最新文献
Medication Errors: An Update From the Central Region of Ghana Synergistic Inhibitory Effect of Gliquidone Against Cisplatin-Resistant Human Lung Adenocarcinoma TH-302: A Highly Selective Hypoxia-Activated Prodrug for Treating PARP Inhibitor–Resistant Cancers Potential Role of APC Mutations in the Prognosis and Targeted Therapy of Gastric Adenocarcinoma The Evaluation for Expandable Applications of Tislelizumab in First-Line Treatment for Advanced Gastric Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1